Back to today’s briefing

Story perspectives

New Antibody Recommendation Offers Hope Against RSV for Infants

6/26/2025

50 5

Summary

Story summary

Infants under 8 months may soon have a powerful ally against respiratory syncytial virus (RSV) as the Advisory Committee on Immunization Practices (ACIP) has recommended Merck's monoclonal antibody, clesrovimab. This pivotal move comes after a significant panel overhaul led by Health and Human Services Secretary Robert F. Kennedy Jr., with the CDC's final approval still awaited, leaving many families hopeful for enhanced vaccine access.

1 of 1

Story summary

Infants under 8 months may soon have a powerful ally against respiratory syncytial virus (RSV) as the Advisory Committee on Immunization Practices (ACIP) has recommended Merck's monoclonal antibody, clesrovimab. This pivotal move comes after a significant panel overhaul led by Health and Human Services Secretary Robert F. Kennedy Jr., with the CDC's final approval still awaited, leaving many families hopeful for enhanced vaccine access.